 Neurosyphilis human immunodeficiency virus type individuals prospective study prevalence neurosyphilis human immunodeficiency virus type -seropositive HIV+ persons course study neurological complications infection sixty-six asymptomatic HIV+ subjects symptomatic HIV+ subjects at-risk HIV- control underwent cerebrospinal fluid CSF analysis entry longitudinal study Three asymptomatic HIV+ subjects reactive CSF VDRL test reactive CSF fluorescent treponemal antibody-absorption FTA-ABS test subjects history early syphilis reactive serum rapid plasma reagin test symptomatic HIV+ subjects patient dementia reactive CSF VDRL test fluorescent treponemal antibody-absorption test Subjective improvement cognitive skills high-dose intravenous penicillin therapy subject penicillin-responsive myelopathy reactive CSF fluorescent treponemal antibody-absorption test result nonreactive CSF VDRL neurosyphilis common population asymptomatic HIV+ subjects responsible neurological disease significant minority symptomatic HIV+ persons Cerebrospinal fluid examination HIV+ persons history syphilis serological evidence syphilis prior treatment neurosyphilis differential diagnosis neurological disease HIV+ person